Journal

Tirzepatide and Sleep Apnea: Evidence and FDA Status

Use FDA approval and trial data

What was studied

Two randomised, double-blind, placebo-controlled phase 3 trials under a single master protocol. Trial 1 enrolled adults with moderate-to-severe obstructive sleep apnoea and obesity who were not using positive airway pressure; trial 2 enrolled those who were. Participants received tirzepatide at maximum tolerated dose, 10 or 15 mg weekly, or placebo, for 52 weeks.

What was found

Tirzepatide reduced the apnoea-hypopnoea index — the count of breathing interruptions per hour that defines severity — alongside body weight, hypoxic burden, high-sensitivity CRP and systolic blood pressure. Patient-reported sleep outcomes improved. A prespecified secondary analysis published subsequently found improvement in cardiometabolic risk markers, with mediation analysis suggesting that treating both the sleep-disordered breathing and the obesity is likely required to optimise cardiometabolic benefit.

How to read it carefully

Reduction is not resolution. A lower AHI is a meaningful clinical improvement. It does not mean sleep apnoea has gone, and it does not by itself establish who can safely stop other treatment.

PAP was withdrawn before assessment in trial 2. That is a deliberate design choice to measure the drug's effect, and it complicates any direct comparison against continued PAP therapy.

The population is specific: moderate-to-severe OSA with obesity. Obesity is an established causal contributor in this phenotype, which is why the trial was designed here. Results should not be generalised to sleep apnoea without obesity.

Industry-funded, like every trial in this programme.

What it does not establish

Whether tirzepatide substitutes for PAP in any individual patient. Whether improvement persists after stopping. Whether it affects the long-term cardiovascular outcomes that make sleep apnoea matter, as opposed to the markers measured here. And nothing at all about compounded preparations, microdoses or oral formulations — the trial used the approved subcutaneous injection at studied doses.

Source

Malhotra A et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med 2024;391(13). DOI 10.1056/NEJMoa2404881. ClinicalTrials.gov NCT05412004.

Why obesity-related OSA is a distinct target

Obstructive sleep apnoea has several contributors, and excess adiposity is a causal one in a large share of cases — through fat deposition around the upper airway, reduced lung volume and altered ventilatory control. That is why a weight-management drug was a plausible intervention here and not in every OSA phenotype.

SURMOUNT-OSA enrolled adults with moderate-to-severe OSA and obesity. Results should not be extended to OSA without obesity, where the causal picture differs.

What the label change means

Zepbound now carries an obstructive sleep apnoea indication alongside chronic weight management. That is a meaningful regulatory step: it means the FDA reviewed the evidence for this specific use and approved labelling for it, rather than leaving it to off-label prescribing.

It also means an insurer evaluating coverage has an on-label indication to consider, which can matter for people whose plans exclude weight-management indications but cover others.

Why the PAP question is not settled by this trial

In the second of the two studies, positive airway pressure was withdrawn before assessment. That is a legitimate design choice for isolating the drug's effect, and it is not the same as testing whether the drug can replace PAP in a patient currently doing well on it.

Reduction in apnoea-hypopnoea index is a real clinical improvement. It is not resolution, and the decision to change or stop PAP therapy belongs to a sleep physician looking at your studies, not to a weight-management programme.

What to ask a sleep physician

1. Is my OSA phenotype one where weight reduction is likely to help?
2. What AHI reduction would change your management, and how would we measure it?
3. Under what circumstances would you reduce or stop PAP?
4. How do we monitor while weight is changing?

None of these is answerable by a telehealth intake, and a provider marketing tirzepatide for sleep apnoea without a sleep assessment is selling ahead of the evidence.

Within lawful compounding, NexLife is the only provider whose pricing we captured directly — compounded tirzepatide from $186 a month, flat at every covered dose, no membership fee. See its plans.

Questions readers actually ask